Marfloquin Tablets 20mg (pack of 100)

Target species Marfloquin 5 mg tablets are indicated for use in cats and dogs. Marfloquin 20 mg and 80 mg tablets are indicated for use in dogs only. Indications for use Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. In dogs: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis); urinary tract infections (UTI) associated or not with prostatitis or epididymitis; respiratory tract infections. In cats (Marfloquin 5 mg tablet only): skin and soft tissue infections (wounds, abscesses, phlegmons); upper respiratory tract infections. Contra-indications Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. Do not use in cats aged less than 16 weeks. Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones or to any of the excipients of the product. Do not use Marfloquin 20 mg tablets or Marfloquin 80 mg tablets in cats. Special warnings for each target species A low urinary pH could have an inhibitory effect on the activity of marbofloxacin. Pyoderma occurs mostly secondary to an underlying disease, thus, it is advisable to determine the underlying cause and to treat the animal accordingly. Special precautions for use In Animals High doses of some fluoroquinolones may have epileptogenic potential. Cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy. However, at the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats. In particular, no lesions of the articular joints were encountered in clinical studies at the recommended dose rate. Official and local antimicrobial policies should be taken in to account when the veterinary medicinal product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Whenever possible, use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the (fluoro)quinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross-resistance. By the person administering the veterinary medicinal product to animals People with known hypersensitivity to (fluoro)quinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wash hands after use. Adverse reactions Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment. Use during pregnancy, lactation or lay Studies in laboratory animals (rat, rabbit) showed no embryotoxicity, teratogenicity and maternotoxicity with marbofloxacin at therapeutic doses. However no specific studies have been carried out in pregnant or lactating cats and dogs. Therefore, in these classes of animals, use only according to the benefit/risk assessment by the responsible veterinarian. Interactions Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron). In such cases, the bioavailability of marbofloxacin may be reduced. Concurrent administration of theophylline products may be followed by inhibited theophylline clearance.